

# Oliver Pfaar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9276282/publications.pdf>

Version: 2024-02-01

235  
papers

14,134  
citations

14655

66  
h-index

25787

108  
g-index

260  
all docs

260  
docs citations

260  
times ranked

7727  
citing authors

#	ARTICLE	IF	CITATIONS
1	One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 454-468.	5.7	39
2	Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 343-345.e2.	3.8	11
3	Perceptions of adolescents and young adults with allergy and/or asthma and their parents on EAACI guideline recommendations about transitional care: A European survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1094-1104.	5.7	7
4	Development and validation of combined symptom& medication scores for allergic rhinitis*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2147-2162.	5.7	32
5	Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient& reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS&24 and SINUS&52 studies. <i>Clinical and Experimental Allergy</i> , 2022, 52, 244-249.	2.9	5
6	EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1667-1684.	5.7	12
7	Novel adaptive design for allergen immunotherapy clinical trials. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1950-1951.	5.7	0
8	Allergic patients during the COVID&19 pandemic& Clinical practical considerations: An European Academy of Allergy and Clinical Immunology survey. <i>Clinical and Translational Allergy</i> , 2022, 12, e12097.	3.2	13
9	Development of the EAACI% season definition a backup for a global application. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1315-1317.	5.7	0
10	COVID&19& vaccination in patients receiving allergen immunotherapy (AIT) or biologicals& EAACI recommendations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2313-2336.	5.7	12
11	Effects of non&steroidal anti&inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID&19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2337-2354.	5.7	9
12	Allergen immunotherapy during the COVID&19 pandemic& A survey of the German Society for Allergy and Clinical Immunology. <i>Clinical and Translational Allergy</i> , 2022, 12, e12134.	3.2	6
13	Allergen immunotherapy in MASK&air users in real&life: Results of a Bayesian mixed&effects model. <i>Clinical and Translational Allergy</i> , 2022, 12, e12128.	3.2	9
14	Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK&air<sup>A</sup></sup> real&world data. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2699-2711.	5.7	17
15	Automatic market research of mobile health apps for the self&management of allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2022, 52, 1195-1207.	2.9	9
16	Epidemiology and treatment of patients with Chronic rhinosinusitis with nasal polyps in Germany& A claims data study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2725-2736.	5.7	4
17	Care with allergen immunotherapy for allergic respiratory diseases in Germany & Predictors and deficits. <i>Clinical and Experimental Allergy</i> , 2022, , .	2.9	3
18	Comparison of rhinitis treatments using <sc>MASK</sc>&air& data and considering the minimal important difference. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3002-3014.	5.7	8

#	ARTICLE	IF	CITATIONS
19	Placebo effects in allergen immunotherapy – An EAACI Task Force Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 629-647.	5.7	31
20	EAACI Biologicals Guidelines – Recommendations for severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 14-44.	5.7	156
21	COVID-19 pandemic: Practical considerations on the organization of an allergy clinic – An EAACI/ARIA Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 648-676.	5.7	79
22	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 168-190.	5.7	46
23	ARIA – EAACI statement on asthma and COVID-19 (June 2, 2020). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 689-697.	5.7	57
24	COVID-19: A series of important recent clinical and laboratory reports in immunology and pathogenesis of SARS-CoV-2 infection and care of allergy patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 622-625.	5.7	11
25	Health care situation in patients with allergic respiratory diseases with special focus on specific immunotherapy. <i>Allergo Journal International</i> , 2021, 30, 39-45.	2.0	3
26	Spices to Control COVID-19 Symptoms: Yes, but Not Only – <i>International Archives of Allergy and Immunology</i> , 2021, 182, 489-495.	2.1	23
27	Legends of allergy and immunology: Anthony J. Frew – A true European advocate of allergology and clinical immunology. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1285-1287.	5.7	0
28	Noninvasive and minimally invasive techniques for the diagnosis and management of allergic diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1010-1023.	5.7	21
29	Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1041-1052.	5.7	38
30	A 300 IR sublingual tablet is an effective, safe treatment for house dust mite – induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1020-1030.e10.	2.9	50
31	COVID-19 vaccination and allergen immunotherapy (AIT) - A position paper of the German Society for Applied Allergology (AeDA) and the German Society for Allergology and Clinical Immunology (DGAKI). <i>Allergologie Select</i> , 2021, 5, 251-259.	3.1	9
32	Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 324-338.	2.1	33
33	COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) – A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergo. <i>Allergologie Select</i> , 2021, 5, 140-147.	3.1	28
34	Anti-IgE: A treatment option in allergic rhinitis?. <i>Allergologie Select</i> , 2021, 5, 119-127.	3.1	7
35	Severe allergic reactions to the COVID-19 vaccine – statement and practical consequences. <i>Allergologie Select</i> , 2021, 5, 26-28.	3.1	33
36	First evaluation of a symbiotic food supplement in an allergen exposure chamber in birch pollen allergic patients. <i>World Allergy Organization Journal</i> , 2021, 14, 100494.	3.5	14

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2337-2353.	5.7	78
38	Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1033-1045.	2.9	8
39	Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA <sup>2</sup> LEN consensus. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2354-2366.	5.7	31
40	The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1805-1812.	3.8	14
41	Technical standards in allergen exposure chambers worldwide – an EAACI Task Force Report. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3589-3612.	5.7	23
42	The need for Pan-European automatic pollen and fungal spore monitoring: A stakeholder workshop position paper. <i>Clinical and Translational Allergy</i> , 2021, 11, e12015.	3.2	18
43	One Hundred Ten Years of Allergen Immunotherapy: A Broad Look Into the Future. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1791-1803.	3.8	23
44	Allergic reactions to COVID-19 vaccinations – unveiling the secret(s). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1621-1623.	5.7	8
45	Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1640-1660.	5.7	72
46	Effects of allergen immunotherapy in the MASK-air study: a proof-of-concept analysis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3212-3214.	5.7	14
47	COVID-19 pandemic and allergen immunotherapy – an EAACI survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3504-3516.	5.7	26
48	Allergen immunotherapy: The growing role of observational and randomized trial – Real World Evidence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2663-2672.	5.7	39
49	Messages for patients and relatives from the 2021 update of the guideline on acute therapy and management of anaphylaxis. <i>Allergo Journal International</i> , 2021, 30, 243-248.	2.0	9
50	Management of anaphylaxis due to COVID-19 vaccines in the elderly. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2952-2964.	5.7	16
51	Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK-air®. <i>Clinical and Translational Allergy</i> , 2021, 11, e12062.	3.2	31
52	Guideline (S2k) on acute therapy and management of anaphylaxis: 2021 update. <i>Allergo Journal International</i> , 2021, 30, 1-25.	2.0	78
53	Effects of Patients'™ Expectation in Dermatology: Evidence from Experimental and Clinical Placebo Studies and Implications for Dermatologic Practice and Research. <i>Dermatology</i> , 2021, 237, 857-871.	2.1	7
54	Precision medicine reaching out to the patients in allergology – a German-Japanese workshop report. <i>Allergologie Select</i> , 2021, 5, 162-179.	3.1	1

#	ARTICLE	IF	CITATIONS
55	ARIA 2019 Care Pathways for Allergic Rhinitis in the Kuwait Health Care System. Medical Principles and Practice, 2021, 30, 320-330.	2.4	0
56	Nonpharmacological measures to prevent allergic symptoms in pollen allergy: A critical review. Allergologie Select, 2021, 5, 349-360.	3.1	7
57	ARIA 2019 Care Pathways for Allergic Rhinitis in the Kuwait Health Care System. Medical Principles and Practice, 2021, 30, 320-330.	2.4	0
58	The role of mobile health technologies in allergy care: An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 259-272.	5.7	95
59	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. Journal of Allergy and Clinical Immunology, 2020, 145, 70-80.e3.	2.9	272
60	Pollen season is reflected on symptom load for grass and birch pollen-induced allergic rhinitis in different geographic areas—An EAACI Task Force Report. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1099-1106.	5.7	34
61	“Whole” vs. “fragmented” approach to EAACI pollen season definitions: A multicenter study in six Southern European cities. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1659-1671.	5.7	21
62	State-of-the-art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 746-760.	5.7	42
63	Current transition management of adolescents and young adults with allergy and asthma: a European survey. Clinical and Translational Allergy, 2020, 10, 40.	3.2	17
64	Allergen Immunotherapy (AIT) in children: a vulnerable population with its own rights and legislation “ summary of EMA-initiated multi-stakeholder meeting on Allergen Immunotherapy (AIT) for children, held at Paul-Ehrlich-Institut, Langen, Germany, 16.1.2019. Clinical and Translational Allergy, 2020, 10, 28.	3.2	8
65	Allergen exposure chambers: implementation in clinical trials in allergen immunotherapy. Clinical and Translational Allergy, 2020, 10, 33.	3.2	12
66	Therapy of allergic rhinitis in routine care: evidence-based benefit assessment of freely combined use of various active ingredients. Allergo Journal International, 2020, 29, 129-138.	2.0	5
67	Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 3039-3068.	5.7	127
68	Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study. Clinical and Translational Allergy, 2020, 10, 62.	3.2	34
69	Allergen Immunotherapy in Children User’s Guide. Pediatric Allergy and Immunology, 2020, 31, 1-101.	2.6	169
70	A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2503-2541.	5.7	95
71	Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2764-2774.	5.7	75
72	Is diet partly responsible for differences in COVID-19 death rates between and within countries?. Clinical and Translational Allergy, 2020, 10, 16.	3.2	97

#	ARTICLE	IF	CITATIONS
73	EAACI Guidelines on the effective transition of adolescents and young adults with allergy and asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2734-2752.	5.7	76
74	The need for improved transition and services for adolescent and young adult patients with allergy and asthma in all settings. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2731-2733.	5.7	3
75	Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2440-2444.	5.7	114
76	Algorithms in allergen immunotherapy in allergic rhinoconjunctivitis. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2411-2414.	5.7	22
77	IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. World Allergy Organization Journal, 2020, 13, 100080.	3.5	245
78	The development of birch pollen seasons over 30 years in Munich, Germany – An EAACI Task Force report*. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 3024-3026.	5.7	9
79	Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air App. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1672-1688.	5.7	32
80	Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1546-1554.	5.7	87
81	Clinical trials in allergen immunotherapy in the age group of children and adolescents: current concepts and future needs. Clinical and Translational Allergy, 2020, 10, 11.	3.2	9
82	In vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan – An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2161-2169.	5.7	23
83	Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA. Allergologie Select, 2020, 4, 44-52.	3.1	23
84	Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic. Allergologie Select, 2020, 4, 53-68.	3.1	38
85	Prioritizing Research Challenges and Funding for Allergy and Asthma and the Need for Translational Research – The European Strategic Forum on Allergic Diseases. PediatriĀeskaĀ FarmakologiĀ, 2020, 16, 281-295.	0.4	0
86	2019 ARIA Care Pathways for Allergic Rhinitis-Turkey. Turkish Thoracic Journal, 2020, 21, 122-133.	0.6	2
87	Next-Generation Allergic Rhinitis Care in Singapore: 2019 ARIA Care Pathways. Annals of the Academy of Medicine, Singapore, 2020, 49, 885-896.	0.4	0
88	Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis. Rhinology, 2019, 57, 49-56.	1.3	10
89	ARIA masterclass 2018: From guidelines to real-life implementation. Rhinology, 2019, 57, 0-0.	1.3	6
90	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergo Journal International, 2019, 28, 255-276.	2.0	22

#	ARTICLE	IF	CITATIONS
91	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseasesâ€”Meeting Report (Part 1). Journal of Thoracic Disease, 2019, 11, 3633-3642.	1.4	11
92	Contraindications to immunotherapy: a global approach. Clinical and Translational Allergy, 2019, 9, 45.	3.2	27
93	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clinical and Translational Allergy, 2019, 9, 44.	3.2	87
94	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseasesâ€”Meeting Report (Part 2). Journal of Thoracic Disease, 2019, 11, 4072-4084.	1.4	15
95	Development of subcutaneous allergen immunotherapy (partÂ2): preventive aspects and innovations. Allergo Journal International, 2019, 28, 107-119.	2.0	13
96	Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2293-2311.	5.7	76
97	Prioritizing research challenges and funding for allergy and asthma and the need for translational researchâ€”The European Strategic Forum on Allergic Diseases. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2064-2076.	5.7	39
98	<sc>EAACI</sc> Guidelines on Allergen Immunotherapy: House dust miteâ€”driven allergic asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 855-873.	5.7	191
99	Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. Journal of Allergy and Clinical Immunology, 2019, 144, 135-143.e6.	2.9	101
100	Evolution of subcutaneous allergen immunotherapy (partÂ1): from first developments to mechanism-driven therapy concepts. Allergo Journal International, 2019, 28, 78-95.	2.0	16
101	Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. Clinical and Translational Allergy, 2019, 9, 16.	3.2	81
102	Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma. Journal of Allergy and Clinical Immunology, 2019, 143, 970-977.	2.9	30
103	2019 ARIA Care pathways for allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2087-2102.	5.7	140
104	Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2511-2523.	3.8	44
105	Strong dose response after immunotherapy with PQ grass using conjunctival provocation testing. World Allergy Organization Journal, 2019, 12, 100075.	3.5	11
106	Perspectives in allergen immunotherapy: 2019 and beyond. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 3-25.	5.7	113
107	From ARIA guidelines to the digital transformation of health in rhinitis and asthma multimorbidity. European Respiratory Journal, 2019, 54, 1901023.	6.7	17
108	<sc>ARIA</sc> pharmacy 2018 â€œAllergic rhinitis care pathways for community pharmacyâ€” Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1219-1236.	5.7	52

#	ARTICLE	IF	CITATIONS
109	Adherence to treatment in allergic rhinitis using mobile technology. The <sc>MASK</sc> Study. <i>Clinical and Experimental Allergy</i> , 2019, 49, 442-460.	2.9	73
110	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 864-879.	2.9	103
111	Intralymphatic Immunotherapy: Update and Unmet Needs. <i>International Archives of Allergy and Immunology</i> , 2019, 178, 141-149.	2.1	71
112	Comparison of International Systemic Adverse Reactions Due to Allergen Immunotherapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1298-1305.e3.	3.8	11
113	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. <i>Allergologie Select</i> , 2019, 3, 22-50.	3.1	70
114	Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the <sc>MASK</sc> study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1622-1631.	5.7	69
115	Clinical trials in allergen immunotherapy: current concepts and future needs. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1775-1783.	5.7	52
116	EAACI Position paper on the standardization of nasal allergen challenges. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1597-1608.	5.7	161
117	EAACI guidelines on allergen immunotherapy: Executive statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 739-743.	5.7	120
118	Treatment of allergic rhinitis using mobile technology with real-world data: The <sc>MASK</sc> observational pilot study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1763-1774.	5.7	94
119	Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 497-509.e9.	2.9	84
120	International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. <i>International Forum of Allergy and Rhinology</i> , 2018, 8, 108-352.	2.8	273
121	Ragweed sublingual tablet immunotherapy: part I – evidence-based clinical efficacy and safety. <i>Immunotherapy</i> , 2018, 10, 605-616.	2.0	8
122	Ultra-short-course booster allergen immunotherapy. <i>Immunotherapy</i> , 2018, 10, 525-528.	2.0	0
123	Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1842-1850.	5.7	44
124	Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (<sc>MACVIA</sc> – <sc>ARIA</sc>) – <sc>EIP</sc> on <sc>AHA</sc> Twinning Reference Site (<sc>GARD</sc> research demonstration project). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 77-92.	5.7	54
125	Computational validation of the recently proposed pollen season definition criteria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 5-7.	5.7	20
126	<sc>EAACI</sc> guidelines on allergen immunotherapy: Hymenoptera venom allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 744-764.	5.7	305





#	ARTICLE	IF	CITATIONS
145	Ragweed sublingual tablet immunotherapy: part II – practical considerations and pertinent issues. Immunotherapy, 2018, 10, 617-626.	2.0	4
146	New European Academy of Allergy and Clinical Immunology definition on pollen season mirrors symptom load for grass and birch pollen-induced allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1851-1859.	5.7	44
147	Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study. World Allergy Organization Journal, 2018, 11, 15.	3.5	33
148	Rhinology Future Debates 2017 by <scp>EUFOREA</scp>: Novel treatments and surgical solutions in rhinology. Clinical Otolaryngology, 2018, 43, 1429-1438.	1.2	3
149	Provocative proposal for a revised nomenclature for allergy and other hypersensitivity diseases. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1939-1940.	5.7	10
150	Sublingual immunotherapy with house dust mite tablets in children – The evidence-based journey of allergen immunotherapy proceeds. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2271-2273.	5.7	3
151	AIT mit seltenen Allergenen: Eine (gesundheitspolitische) Bestandsaufnahme. Allergologie, 2018, 41, 416-426.	0.1	3
152	Sublingual Immunotherapy Dosing Regimens: What Is Ideal?. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1-10.	3.8	20
153	Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1156-1173.	5.7	275
154	Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future – an <scp>EAACI</scp> Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1035-1042.	5.7	85
155	Novel approaches and perspectives in allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1022-1034.	5.7	68
156	Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care. Allergo Journal International, 2017, 26, 16-24.	2.0	292
157	Clinical validation of a house dust mite environmental challenge chamber model. Journal of Allergy and Clinical Immunology, 2017, 140, 266-268.e5.	2.9	13
158	Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1597-1631.	5.7	233
159	Physicians' experience and opinion on contraindications to allergen immunotherapy: The CONSIT survey. Annals of Allergy, Asthma and Immunology, 2017, 118, 621-628.e1.	1.0	13
160	Defining pollen exposure times for clinical trials of allergen immunotherapy for pollen-induced rhinoconjunctivitis – an <scp>EAACI</scp> position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 713-722.	5.7	118
161	Allergen immunotherapy in allergic rhinitis: current use and future trends. Expert Review of Clinical Immunology, 2017, 13, 897-906.	3.0	27
162	Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1825-1848.	5.7	247

#	ARTICLE	IF	CITATIONS
163	Current Standards and Improvements in the Use of SLIT Tablets for Allergen Immunotherapy. Current Treatment Options in Allergy, 2017, 4, 286-289.	2.2	1
164	Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 342-365.	5.7	97
165	EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatric Allergy and Immunology, 2017, 28, 728-745.	2.6	171
166	Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews. Clinical and Translational Allergy, 2017, 7, 25.	3.2	56
167	Dose-response relationship of a new Timothy grass pollen allergoid in comparison with a grass pollen allergoid. Clinical and Experimental Allergy, 2017, 47, 1445-1455.	2.9	16
168	European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 462-472.	5.7	71
169	Allergen immunotherapy for the prevention of allergy: A systematic review and meta-analysis. Pediatric Allergy and Immunology, 2017, 28, 18-29.	2.6	155
170	Validation of the Global Allergy and Asthma European Network (GA2LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber. Journal of Allergy and Clinical Immunology, 2017, 139, 1158-1166.	2.9	32
171	The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): A paediatric assessment. Pediatric Allergy and Immunology, 2017, 28, 60-70.	2.6	71
172	Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews. Clinical and Translational Allergy, 2017, 7, 24.	3.2	49
173	Peak nasal inspiratory flow as outcome for provocation studies in allergen exposure chambers: a GA2LEN study. Clinical and Translational Allergy, 2017, 7, 33.	3.2	15
174	Allergen immunotherapy for the prevention of allergic disease: protocol for a systematic review. Pediatric Allergy and Immunology, 2016, 27, 236-241.	2.6	13
175	Fel d 1 synthetic peptides (Cat PAD) – Good news for cat owners with children?. Pediatric Allergy and Immunology, 2016, 27, 666-670.	2.6	1
176	Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. Clinical and Translational Allergy, 2016, 6, 41.	3.2	24
177	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy, 2016, 6, 47.	3.2	121
178	Comparison of allergenic extracts from different origins: the value of the FDA's bioequivalent allergy unit (BAU). Expert Review of Clinical Immunology, 2016, 12, 733-739.	3.0	9
179	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 367-374.e2.	2.9	128
180	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). Clinical and Translational Allergy, 2016, 6, 29.	3.2	47

#	ARTICLE	IF	CITATIONS
181	Patient engagement and patient support programs in allergy immunotherapy: a call to action for improving long-term adherence. <i>Allergy, Asthma and Clinical Immunology</i> , 2016, 12, 34.	2.0	18
182	Evidence vs. efficacy in allergen-specific immunotherapy: Considerations using the example of tradable products in Germany. <i>Allergo Journal International</i> , 2016, 25, 38-43.	2.0	8
183	New opportunities for allergen immunotherapy using synthetic peptide immuno-regulatory epitopes (SPIRES). <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1123-1135.	3.0	20
184	Allergen immunotherapy for allergic asthma: protocol for a systematic review. <i>Clinical and Translational Allergy</i> , 2016, 6, 5.	3.2	15
185	Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review. <i>Clinical and Translational Allergy</i> , 2016, 6, 12.	3.2	14
186	A randomized, 5â€arm dose finding study with a mite allergoid <sc>SCIT</sc> in allergic rhinoconjunctivitis patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 967-976.	5.7	39
187	Management of the polyallergic patient with allergy immunotherapy: a practice-based approach. <i>Allergy, Asthma and Clinical Immunology</i> , 2016, 12, 2.	2.0	58
188	A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT â€birch pollen extract for the treatment of allergic rhinitis: results of a phase II study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 99-107.	5.7	44
189	International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 358-368.	2.9	199
190	Sublingual grass and ragweed immunotherapy: Clinical considerationsâ€”a PRACTALL consensus report. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 369-376.	2.9	37
191	Safety and effect on reported symptoms of depigmented polymerized allergen immunotherapy: a retrospective study of 2927 paediatric patients. <i>Pediatric Allergy and Immunology</i> , 2015, 26, 280-286.	2.6	14
192	MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1372-1392.	5.7	160
193	Prospective adherence to specific immunotherapy in Europe (PASTE) survey protocol. <i>Clinical and Translational Allergy</i> , 2015, 5, 17.	3.2	6
194	The effect of a new communication template on anticipated willingness to initiate or resume allergen immunotherapy: an internet-based patient survey. <i>Allergy, Asthma and Clinical Immunology</i> , 2015, 11, 17.	2.0	17
195	Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1â€FV in a randomized controlled trial. <i>Clinical and Translational Allergy</i> , 2015, 5, 28.	3.2	48
196	Allergen immunotherapy for insect venom allergy: protocol for a systematic review. <i>Clinical and Translational Allergy</i> , 2015, 6, 6.	3.2	11
197	Effects of a structured educational intervention on knowledge and emergency management in patients at risk for anaphylaxis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 227-235.	5.7	91
198	Clinically relevant outcome measures for new pharmacotherapy, allergen avoidance and immunotherapy trials in allergic rhinoconjunctivitis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2015, 15, 197-203.	2.3	7

#	ARTICLE	IF	CITATIONS
199	Sublingual Immunotherapy with a Five-Grass Pollen Tablet in Adult Patients with Allergic Rhinitis: An Open, Prospective, Noninterventional, Multicenter Study. <i>BioMed Research International</i> , 2015, 2015, 1-11.	1.9	6
200	Mite-Allergic Rhinitis: How to Evaluate Clinical Efficacy in Allergen-Specific Immunotherapy Trials?. <i>Current Treatment Options in Allergy</i> , 2015, 2, 1-9.	2.2	11
201	Environmental exposure chambers in allergen immunotherapy trials: Current status and clinical validation needs. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 636-643.	2.9	59
202	International consensus on allergy immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 556-568.	2.9	427
203	Clinical contraindications to allergen immunotherapy: an EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 897-909.	5.7	177
204	Quantitative Conjunctival Provocation Test for Controlled Clinical Trials. <i>Methods of Information in Medicine</i> , 2014, 53, 238-244.	1.2	13
205	Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases. <i>Allergo Journal International</i> , 2014, 23, 282-319.	2.0	338
206	Allergen Immunotherapy: Clinical Outcomes Assessment. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 123-129.	3.8	16
207	Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 854-867.	5.7	344
208	A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster protocol. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 1629-1638.	5.7	37
209	Negative Clinical Results from a Randomised, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy of Two Doses of Immunologically Enhanced, Grass Subcutaneous Immunotherapy Despite Dose-Dependent Immunological Response. <i>Clinical Drug Investigation</i> , 2014, 34, 577-586.	2.2	13
210	An EAACI European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI) the methodology. <i>Clinical and Translational Allergy</i> , 2014, 4, 22.	3.2	20
211	A prospective study comparing the efficacy and safety of two sublingual birch allergen preparations. <i>Clinical and Translational Allergy</i> , 2014, 4, 23.	3.2	11
212	Sublingual immunotherapy: World Allergy Organization position paper 2013 update. <i>World Allergy Organization Journal</i> , 2014, 7, 6.	3.5	395
213	Guideline for acute therapy and management of anaphylaxis. <i>Allergo Journal International</i> , 2014, 23, 96-112.	2.0	210
214	The placebo effect in allergen-specific immunotherapy trials. <i>Clinical and Translational Allergy</i> , 2013, 3, 42.	3.2	51
215	Depigmented polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 1306-1313.	5.7	35
216	Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Grass Pollen Preparation. <i>International Archives of Allergy and Immunology</i> , 2013, 160, 420-424.	2.1	20

#	ARTICLE	IF	CITATIONS
217	Adjuvants for immunotherapy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2012, 12, 648-657.	2.3	52
218	Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations. <i>Immunotherapy</i> , 2012, 4, 601-616.	2.0	46
219	EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. <i>Clinical and Translational Allergy</i> , 2012, 2, 20.	3.2	97
220	Research needs in allergy: an EAACI position paper, in collaboration with EFA. <i>Clinical and Translational Allergy</i> , 2012, 2, 21.	3.2	127
221	Immunologic Effect and Tolerability of Intra-Seasonal Subcutaneous Immunotherapy With an 8-Day Up-Dosing Schedule to 10,000 Standardized Quality-Units: A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Clinical Therapeutics</i> , 2012, 34, 2072-2081.	2.5	17
222	A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 272-279.	5.7	59
223	Immunological effects and tolerability of a new fast up dosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 630-637.	5.7	18
224	Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study. <i>Clinical and Experimental Allergy</i> , 2012, 42, 936-945.	2.9	50
225	Cyclamen europaeum nasal spray, a novel phytotherapeutic product for the management of acute rhinosinusitis: a randomized double-blind, placebo-controlled trial. <i>Rhinology</i> , 2012, 50, 37-44.	1.3	29
226	Allergen-Specific Immunotherapy: Which Outcome Measures are Useful in Monitoring Clinical Trials?. <i>Immunology and Allergy Clinics of North America</i> , 2011, 31, 289-309.	1.9	46
227	Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. <i>Clinical and Experimental Allergy</i> , 2011, 41, 1305-1312.	2.9	125
228	Sublingual Allergen-Specific Immunotherapy Adjuvanted with Monophosphoryl Lipid A: A Phase I/IIa Study. <i>International Archives of Allergy and Immunology</i> , 2011, 154, 336-344.	2.1	93
229	Safety of a Depigmented, Polymerized Vaccine for the Treatment of Allergic Rhinoconjunctivitis and Allergic Asthma. <i>American Journal of Rhinology and Allergy</i> , 2010, 24, 220-225.	2.0	19
230	Cluster protocols in SCIT: enough evidence for practical use?. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2010, 10, 188-193.	2.3	16
231	Safety aspects of Cluster immunotherapy with semi-depot allergen extracts in seasonal allergic rhinoconjunctivitis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2010, 267, 245-250.	1.6	14
232	Immunotherapy with depigmented polymerized mixed tree pollen extract: a clinical trial and responder analysis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 1614-1621.	5.7	42
233	Safety of a rush immunotherapy build-up schedule with depigmented polymerized allergen extracts. <i>Allergy and Asthma Proceedings</i> , 2010, 31, 31-38.	2.2	21
234	Safety of Two Cluster Schedules for Subcutaneous Immunotherapy in Allergic Rhinitis or Asthma Patients Sensitized to Inhalant Allergens. <i>International Archives of Allergy and Immunology</i> , 2009, 150, 102-108.	2.1	22

#	ARTICLE	IF	CITATIONS
235	Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial. <i>Annals of Allergy, Asthma and Immunology</i> , 2008, 100, 256-263.	1.0	58